APPENDICES - NIHR Health Technology Assessment Programme

DOI: 10.3310/hta14370 Health Technology Assessment 2010; Vol. 14: No. 37
Seven non-RCTs reported in 11 publications
were identified, which reported on patients with
Barrett’s oesophagus being treated with PDT. 1–11
These were originally to be included in the main
systematic review; however, as 24 publications
reporting 11 RCTs were identified, these less
robust non-randomised designs were subsequently
excluded from the review.
A further 96 publications with study designs that
did not meet the inclusion criteria for the review
were identified. 12–107 The references are listed
below in alphabetical order, they have not been
categorised and may still contain a number of
duplicate publications.
References
Non-randomised controlled trials
1. Gross SA, Gill KR, Wolfsen HC. Comparative
outcomes of photodynamic therapy and
radiofrequency ablation for the treatment of
Barrett’s esophagus with high grade dysplasia.
Gastrointest Endosc 2008;67:A179.
2. Jamieson N, Mosse A, Thorpe S, Novelli M, Bown
S, Lovat L. High-grade dysplasia in Barrett’s
esophagus: successful ablation by photodynamic
therapy with ALA requires intensive therapy.
Gastroenterology 2003;124:A298.
3. Jamieson NF, Thorpe S, Mosse A, Bown SG, Lovat
LB. High grade dysplasia in Barrett’s oesophagus:
successful ablation by photodynamic therapy with
ALA requires intensive therapy. Gut 2003;52:73.
4. Mackenzie G, Clark BR, Selvasekar C, Jamieson N,
Novelli M, Thorpe S, et al. Photodynamic therapy
with 5 aminolevulinic acid for high grade dysplasia
in Barrett’s esophagus: longterm follow-up of 51
patients. Gastroenterology 2005;128:A238.
5. Mackenzie GD, Clark B, Selvasekar CR, Jamieson
NF, Novelli MR, Thorpe SM, et al. Photodynamic
therapy with 5 aminolevulinic acid for high grade
dysplasia in Barrett’s oesophagus: long term followup
of 51 patients. Gut 2005;54:53.
6. Mackenzie GD, Jamieson NF, Novelli MR, Mosse
CA, Clark BR, Thorpe SM, et al. How light
dosimetry influences the efficacy of photodynamic
therapy with 5-aminolaevulinic acid for ablation of
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
Appendix 7
Barrett’s oesophagus scoping
high-grade dysplasia in Barrett’s esophagus. Lasers
Med Sci 2008;23:203–10.
7. May A, Gossner L, Pech O, Fritz A, Gunter E, Mayer
G, et al. Local endoscopic therapy for intraepithelial
high-grade neoplasia and early adenocarcinoma in
Barrett’s oesophagus: acute-phase and intermediate
results of a new treatment approach. Eur J
Gastroenterol Hepatol 2002;14:1085–91.
8. Mellidez JC, Mackenzie G, Selvasekar C, Novelli
M, Thorpe S, Mosse C, et al. Reversal of Barrett’s
esophagus following photodynamic therapy using
high dose 5 aminolevulinic acid activated by red or
green laser light. Gastroenterology 2005;128:A239.
9. Panjehpour M, Overholt BF, Phan MN, Haydek JM.
Optimization of light dosimetry for photodynamic
therapy of Barrett’s esophagus: efficacy vs.
incidence of stricture after treatment. Gastrointest
Endosc 2005;61:13–18.
10. Panjehpour M, Phan MN, Overholt BF, Haydek JM.
Optimization of light dosimetry for photodynamic
therapy of Barrett’s esophagus. SPIE Proceedings
Series 2004;5315:100–6.
11. Phan MN, Panjehpour M, Overholt BF.
Optimization of photodynamic therapy for
Barrett’s esophagus: treatment efficacy and stricture
incidence as a function of light dose. Gastroenterology
2004;126:A178.
Other scoping publications
12. Photodynamic therapy with porfimer sodium
for ablation of high-grade dysplasia in Barrett’s
esophagus: international, partially blinded,
randomized phase III trial. [Erratum published in
Gastrointest Endosc 2005;62:488–498.] Gastrointest
Endosc 2006;63:359.
13. Ackroyd R, Brown NJ, Davis MF, Stephenson TJ,
Stoddard CJ, Reed MW. Aminolevulinic acidinduced
photodynamic therapy: safe and effective
ablation of dysplasia in Barrett’s esophagus. Dis
Esophagus 2000;13:18–22.
14. Ackroyd R, Brown NJ, Davis MF, Stephenson
TJ, Stoddard CJ, Reed MWR. Aminolaevulinic
acid-induced photodynamic therapy in the
treatment of dysplastic Barrett’s oesophagus and
adenocarcinoma. Lasers Med Sci 1999;14:278–85.
151